On November 18, 2026, Oracle introduced Oracle Life Sciences AI Agents and said the experience was available to early adopters. Oracle describes the agents as supporting portfolio monitoring, trial planning and trial conduct.

The announced workflow leaves review and approval of proposed actions with people.

What Oracle says the agents do

Oracle says the agents draw insights from Oracle Life Sciences applications and supported third-party data sources. One example is monitoring study performance, identifying likely drivers of changes in key performance indicators (KPIs), and recommending operational actions aligned with a trial protocol.

Human approval and planned capabilities

Users review the recommendations and approve proposed actions before execution, according to Oracle. The company also listed clinical data management, post-trial analytics, trial design and post-market workflows as planned enhancements.